Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN)

33 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q1 2025.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.57M shares of 81.1M outstanding shares and own 9.33% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (5.71M shares), Pictet Asset Management Holding SA (1.25M shares), VICTORY CAPITAL MANAGEMENT INC (553K shares), RICE HALL JAMES & ASSOCIATES, LLC (363K shares), PRINCIPAL FINANCIAL GROUP INC (209K shares), Hennion & Walsh Asset Management, Inc. (199K shares), Bank of New York Mellon Corp (198K shares), RHUMBLINE ADVISERS (105K shares), ALPS ADVISORS INC (61.5K shares), and Moody Aldrich Partners LLC (57.8K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.